Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

References

• MortonLMWangSSDevesaSSHartgePWeisenburgerDDLinetMSLymphoma incidence patterns by WHO subtype in the united states, 1992–2001Blood200610726527616150940
   PubMed Web of Science ®Google Scholar
• GribbenJGHow I treat indolent lymphomaBlood20071094617462617311989
   PubMed Web of Science ®Google Scholar
• JunlenHRPetersonSKimbyEFollicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish lymphoma registry studyLeukemia20152966867625151959
   PubMed Web of Science ®Google Scholar
• RedaelliALaskinBLStephensJMBottemanMFPashosCLThe clinical and epidemiological burden of chronic lymphocytic leukaemiaEur J Cancer Care (Engl)20041327928715196232
   PubMed Web of Science ®Google Scholar
• DiehlLFKarnellLHMenckHRThe American college of surgeons commission on cancer and the American cancer society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemiaCancer1999862684269210594864
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood200811297598018411418
   PubMed Web of Science ®Google Scholar
• GoedeVHallekMPharmacotherapeutic management of chronic lymphocytic leukaemia in patients with comorbidities: new agents, new hopeDrugs Aging2015321187788626446155
   PubMed Web of Science ®Google Scholar
• EichhorstBFinkAMBuschRFrontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physica lly fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the german CLL study group (GCLLSG)(CLL10 study) [abstract 19]Abstract presented at: 56th American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 6–9, 2014San Francisco, CA
   Google Scholar
• LunningMAVoseJMManagement of indolent lymphoma: where are we now and where are we goingBlood Rev20122627928823063143
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet20133811203121023433739
   PubMed Web of Science ®Google Scholar
• StevensonFKCaligaris-CappioFChronic lymphocytic leukemia: revelations from the B-cell receptorBlood20041034389439514962897
   PubMed Web of Science ®Google Scholar
• DavidsMSBrownJRTargeting the B cell receptor pathway in chronic lymphocytic leukemiaLeuk Lymphoma2012532362237022616724
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSETargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaN Engl J Med2013369324223782158
   PubMed Web of Science ®Google Scholar
• WangYZhangLLChamplinREWangMLTargeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignanciesClin Pharmacol Ther20159745546825669675
   PubMed Web of Science ®Google Scholar
• MarkhamAIdelalisib: first global approvalDrugs2014741701170725187123
   PubMed Web of Science ®Google Scholar
• VanhaesebroeckBGuillermet-GuibertJGrauperaMBilangesBThe emerging mechanisms of isoform-specific PI3K signallingNat Rev Mol Cell Biol20101132934120379207
   PubMed Web of Science ®Google Scholar
• PuriKDGoldMRSelective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignanciesFront Immunol2012325622936933
   PubMed Web of Science ®Google Scholar
• DongSGuinnDDubovskyJAIPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cellsBlood20141243583358625258342
   PubMed Web of Science ®Google Scholar
• SciavolinoPJA tale of two isoforms: PI3K delta and gammaTargeted Oncology [serial online, cited December 1, 2015]4302015 Available from: http://www.targetedonc.com/publications/targeted-therapies-cancer/2015/april-2015/a-tale-of-two-isoforms-pi3k-delta-and-gammaAccessed November 10, 2015
   Google Scholar
• BernalAPastoreRDAsgaryZSurvival of leukemic B cells promoted by engagement of the antigen receptorBlood2001983050305711698290
   PubMed Web of Science ®Google Scholar
• YoungRMStaudtLMTargeting pathological B cell receptor signalling in lymphoid malignanciesNat Rev Drug Discov20131222924323449308
   PubMed Web of Science ®Google Scholar
• RamanathanSJinFSharmaSKearneyBPClinical pharmacokinetic and pharmacodynamic profile of idelalisibClin Pharmacokinet Epub8152015
   Web of Science ®Google Scholar
• BrownJRByrdJCCoutreSEIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemiaBlood20141233390339724615777
   PubMed Web of Science ®Google Scholar
• FurmanRRSharmanJPCoutreSEIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaN Engl J Med2014370997100724450857
   PubMed Web of Science ®Google Scholar
• O’BrienSMLamannaNKippsTJA phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemiaBlood2015126252686269426472751
   PubMed Web of Science ®Google Scholar
• ZelenetzADRobakTCoiffierBIdelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 random-ized double-blind placebo-controlled study [late breaking abstract 5]Abstract presented at: 57th American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 5–8, 2015Orlando, FL
   Google Scholar
• GopalAKKahlBSde VosSPI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphomaN Engl J Med20143701008101824450858
   PubMed Web of Science ®Google Scholar
• Zyledig^® [prescribing information]Foster City, CAGilead Sciences, Inc.2014 Available from: http://www.gilead.com/∼/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdfAccessed November 28, 2015
   Google Scholar
• LampsonBLMatosTKimHTIdelalisib given front-line for the treatment of Chronic lymphocytic Leukemia Results in frequent and severe immune-mediated toxicities [abstract 497]Abstract presented at: 57th American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 5–8, 2015Orlando, FL
   Google Scholar
• WeidnerASPanarelliNCGeyerJTIdelalisib-associated colitis: histologic findings in 14 patientsAm J Surg Pathol201539121661166726448188
   PubMed Web of Science ®Google Scholar
• ButlerTMaraventSBoisselleJValdesJFellnerCA review of 2014 cancer drug approvals, with a look at 2015 and beyondP T20154019120525798040
   PubMedGoogle Scholar
• BluntMDSteeleAJPharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemiaLeuk Res Rep20154606326500849
   PubMedGoogle Scholar
• BalakrishnanKPelusoMFuMThe phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLLLeukemia2015291811182225917267
   PubMed Web of Science ®Google Scholar
• ChoudharyGSAl-HarbiSMazumderSMCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignanciesCell Death Dis20156e159325590803
   PubMed Web of Science ®Google Scholar